ReviewPatient preference and adherence2026
Patient Experiences of Intravitreal Anti-Vascular Endothelial Growth Factor Injections for Age-Related Macular Degeneration: A Meta-Synthesis of Qualitative Studies.
Review in Patient preference and adherence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To synthesize evidence from qualitative studies on patients receiving intravitreal anti-vascular endothelial growth factor injections for age-related macular degeneration to explore their treatment burdens and life experiences. Methods: Five databases (PubMed, Web of Science, Embase, Cochrane Library, and CINAHL) were searched on 20 May 2025, with supplementation through hand-searching. The search was restricted to qualitative or mixed-methods studies published in English. The included studies were evaluated and synthesized by two independent reviewers using the Joanna Briggs Institute (JBI) critical appraisal tools and the JBI aggregative integration method. Results: Thirteen studies (2010-2023) from 11 countries were summarized into four themes: barriers to treatment and sources of anxiety, coping strategies and adaptation mechanisms, drivers of treatment adherence, and the impact of doctor-patient engagement. Conclusion: Patients with age-related macular degeneration face significant physical, emotional, and logistical challenges during anti-vascular endothelial growth factor therapy. A series of measures can be integrated into the treatment process to improve patient adherence, including psychological support, structured patient education, and optimized treatment pathways. Registration: PROSPERO CRD420251059151.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.